More specifically, Parasramka et al. (2017) noticed that gemcitabine cytotoxicity was strengthened in low BAP1 expressing CCA cells, and then NEAT1 was enriched in CCA cells after the knockout of BAP1. This evidence concerns the gene BAP1 and cholangiocarcinoma.